SCHEMBL2206967

SCHEMBL2206967

CC[PH]1(O)CCN(C(=O)Cc2ccc(C(=O)Nc3cc(-c4cccs4)ccc3N)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.61
HDAC2 Q92769 6/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2208867 0.90 HDAC1 (0.63) HDAC1HDAC2
SCHEMBL2211137 0.88 HDAC1 (0.65) HDAC1HDAC2
SCHEMBL2210806 0.88 HDAC1 (0.64) HDAC1HDAC2
SCHEMBL2211003 0.87 HDAC1 (0.63) HDAC1HDAC2
SCHEMBL2206970 0.85 HDAC1 (0.61) HDAC1HDAC2
SCHEMBL2206964 0.85 HDAC1 (0.61) HDAC1HDAC2
SCHEMBL2208997 0.83 HDAC1 (0.70) HDAC1HDAC2
SCHEMBL2210797 0.81 HDAC1 (0.61) HDAC1HDAC2
SCHEMBL2210809 0.81 HDAC1 (0.61) HDAC1HDAC2
SCHEMBL2208813 0.81 HDAC2 (0.77) HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK SHARP & DOHME CORP. 2009-10-29 US claimed
US-7981874-B2 Phosphorus derivatives as histone deacetylase inhibitors MERCK SHARP & DOHME CORP. (US) 2011-07-19 US disclosed
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK SHARP & DOHME CORP. 2009-10-29 US disclosed
WO-2008010985-A2 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC5, PPM1A, PTEN HDAC1 4/4885HDAC2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.